Damila Cristina Trufelli

Damila Cristina Trufelli

Auto-generated profile, based on publicly available information

Damila Cristina Trufelli

22Janssen-Cilag Ltda, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
PDF file
VLViviane Lealdini
Viviane Lealdini
DTDamila Cristina Trufelli
Damila Cristina Trufelli
FSFernanda Borges Ferreira da Silva
Fernanda Borges Ferreira da Silva
SNSavia Raquel Costa Normando
Savia Raquel Costa Normando
ECElisa Watanabe Camargo
Elisa Watanabe Camargo
AGAuro del Giglio
Auro del Giglio

29 April 2022 in JCO Global Oncology
Verified
Journal Article
Open access
MPMiguel Pavlovsky
Miguel Pavlovsky
DCDaniel de Iracema Gomes Cubero
Daniel de Iracema Gomes Cubero
GAGladys Patricia Agreda-Vásquez
Gladys Patricia Agreda-Vásquez
AEAlicia Enrico
Alicia Enrico
MMMaria J. Mela-Osorio
Maria J. Mela-Osorio
PVPamella Villanova
Pamella Villanova
PURPOSE: Real-world evidence on non-Hodgkin lymphoma (NHL) management in Latin America is currently lacking. The objective of this study was to describe treatment characteristics and outcomes of NHL in Latin America. METHODS: A total of 2,967 patients with NHL with aggressive and indolent subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), and mucosa-associated lymphoid tissue (MALT) lymphoma, with incident or prevalent diagnosis between 2006 and 2015, were retrospectively identified using clinical charts registered in the Hemato-Oncology Latin America Observational Registry. Associations between treatment regimen and age at diagnosis with clinical outcomes within each subtype were estimated using Cox proportional hazard regression. RESULTS: Most patients with NHL received 1L chemoimmunotherapy, most commonly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with/without rituximab. Five-year survival rates were higher for MALT lymphoma (90.8%) and FL (87.6%) versus DLBCL (69.0%) and MCL (57.1%), with variations between countries. The median overall survival from first relapse for patients with DLBCL was 6.6 years, with lower risk of death for those diagnosed at age < 65 years (hazard ratio = 0.732; P = .0161). Patients achieved a longer median progression-free survival with 1L rituximab-CHOP (R-CHOP) versus CHOP or rituximab, cyclophosphamide, vincristine, and prednisone (RCVP) (7.7 v 3.0 or 1.8 years, respectively). Use of regimens other than R-CHOP was associated with a higher risk of death/progression for patients with DLBCL (rituximab, ifosfamide, carboplatin, and etoposide/ifosfamide, carboplatin, and etoposide) and FL (CHOP). There was no relationship between treatment prescribed and age at diagnosis with outcomes from first/second relapse in DLBCL and FL. CONCLUSION: Differences in treatment outcomes between NHL subtypes were observed, reflecting variations in NHL management and barriers to treatment access in Latin America. These data provide necessary evidence to understand NHL management in this region and highlight the need to improve treatment outcomes for these patients.

17 January 2019 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
LSLuana Carolina Ferreira Fiuza Silva
Luana Carolina Ferreira Fiuza Silva
LALilian Silva Martins de Arruda
Lilian Silva Martins de Arruda
WDWaldec Jorge David
Waldec Jorge David
FCFelipe José Silva Melo Cruz
Felipe José Silva Melo Cruz
DTDamila Cristina Trufelli
Damila Cristina Trufelli
AGAuro del Giglio
Auro del Giglio
To define a predictive factor for pathologic complete response, compare the oncologic outcomes associated with the degree of pathologic response after neoadjuvant chemotherapy, and to analyze pathologic complete response as a prognostic factor for overall survival and progression-free survival. A retrospective study of patients admitted to Hospital Estadual Mário Covas and Hospital Anchieta from 2008 to 2012, with locally advanced breast cancer. Hormone receptor status, HER2 status, histologic and nuclear grade, age upon diagnosis and histological type of the tumor were analyzed. Pathologic evaluation of the tumor was subdivided into pathologic complete response, defined by the absence of tumor; intermediate response, considered as a favorable stage; and poor response, considering low-responder patients. Data obtained were submitted to statistical analysis. The study included 243 patients. There was an association of pathologic complete response with HER-2 negative, histological grade 3, stage III, hormone receptor negative, positive lymph node, older age and more advanced tumors. However, after multivariate analysis the only predictor of pathologic complete response was the presence of negative hormone receptor. By analyzing the prognostic factors, hormone receptor negative was considered as an independent risk factor, and pathologic complete response was considered as an independent protective factor. Hormone receptor negative is predictive of pathologic complete response and is an isolated risk factor for lower progression-free survival and overall survival. Pathologic complete response is a protective factor for these same survival analyses.

14 September 2020 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
ECEdvan Crusoe
Edvan Crusoe
FPFlávia Cristina Fernandes Pimenta
Flávia Cristina Fernandes Pimenta
AMAngelo Maiolino
Angelo Maiolino
NCNelson Siqueira de Castro
Nelson Siqueira de Castro
HPHuiling Pei
Huiling Pei
LHLuciana Barreto Herriot
Luciana Barreto Herriot
Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM). We report results of an early access protocol (EAP) of daratumumab monotherapy for RRMM in a cohort of Brazilian patients. Patients with RRMM and ≥3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or who were double refractory to both a PI and IMiD received daratumumab, 16 mg/kg, intravenously weekly for 8 weeks, biweekly for 16 weeks, and every 4 weeks thereafter until disease progression, unacceptable toxicity, loss of clinical benefit, or study conclusion or if daratumumab became available with reimbursement. Forty-nine patients received ≥1 dose of daratumumab. The median (range) duration of treatment was 6.4 (0.3−11.8) months, with a median (range) of 8 (1−13) treatment cycles. Grade 3/4 treatment-emergent adverse events (TEAEs) were reported in 38.8% of patients, most frequently neutropenia and pneumonia (10.2% each). Seven (14.3%) patients discontinued treatment due to TEAEs; 3 patients discontinued due to daratumumab-related TEAEs. Serious TEAEs occurred in 38.8% of patients. Infusion-related reactions were reported in 25 (51.0%) patients, were primarily grade 1/2, and the majority (23 patients) occurred during the first infusion. Twenty (40.8%) patients achieved a partial response or better; median progression-free survival was 8.25 (95% confidence interval, 5.55–17.54) months. In this EAP, daratumumab monotherapy in Brazilian patients showed a safety and efficacy profile consistent with clinical studies of daratumumab monotherapy in patients with heavily pretreated RRMM. ClinicalTrials.gov identifier: NCT02477891.

13 March 2025 in Blood Advances
Verified
Journal Article
Open access
VHVania Hungria
Vania Hungria
RGRafael Gaiolla
Rafael Gaiolla
KGKenny Mauricio Galvez
Kenny Mauricio Galvez
GRGuillermina Remaggi
Guillermina Remaggi
NSNatalia Schutz
Natalia Schutz
DTDamila Cristina Trufelli
Damila Cristina Trufelli
Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ≥18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. This trial was registered at www.clinicaltrials.gov as #NCT03955900.

21 July 2015 in Brazilian Journal of Otorhinolaryngology
Verified
Journal Article
Open access
DTDamila Cristina Trufelli
Damila Cristina Trufelli
LMLeandro Luongo Matos
Leandro Luongo Matos
TSThaiana Aragão Santana
Thaiana Aragão Santana
FCFábio de Aquino Capelli
Fábio de Aquino Capelli
JKJossi Ledo Kanda
Jossi Ledo Kanda
GJGilberto de Castro Junior
Gilberto de Castro Junior
Chemoradiotherapy for squamous cell carcinoma of the oropharynx (SCCO) provides good results for locoregional disease control, with high rates of complete clinical and pathologic responses, mainly in the neck. To determine whether complete pathologic response after chemoradiotherapy is related to the prognosis of patients with SCCO. Data were prospectively extracted from clinical records of N2 and N3 SCCO patients submitted to a planned neck dissection after chemoradiotherapy. A total of 19 patients were evaluated. Half of patients obtained complete pathologic response in the neck. Distant or locoregional recurrence occurred in approximately 42% of patients, and 26% died. Statistical analysis showed an association between complete pathologic response and lower disease recurrence rate (77.8% vs. 20.8%; p=0.017) and greater overall survival (88.9% vs. 23.3%; p=0.049). The presence of a complete pathologic response after chemoradiotherapy positively influences the prognosis of patients with SCCO.